Genesys Capital:

Life science venture capital

We invest in early stage life science companies that are poised to change lives for the better.

About Genesys

Expertise. Experience. Insight.

Genesys Snapshot:

  • $300M+ Raised
  • $250M+ Invested
  • 5 Funds
  • 38 Companies
  • 18 Exits

Genesys Capital invests in and builds companies in the high-growth sectors of biotechnology, pharmaceuticals and medical technology. We have a proven track record of identifying emerging bioscience opportunities, and transforming them into commercially successful companies. That track record is fuelled by robust industry relationships, broad business expertise, and a deep understanding of the life sciences sector.

Genesys has generated more than 18 exits from 38 portfolio companies and has invested more than $250M. Our third institutional fund is closed and we’re actively considering new, high-potential life science companies for investment.

Why Genesys succeeds

Robust industry relationships, deep subject area knowledge, and proven insights let us identify viable companies early… and arm them to perform.

Stable and proven team

Our team has worked together for two decades of successful and continuous partnership.

Robust industry relationships

Long standing relationships with leading North American research institutes and universities provide us with early insights into top-tier research discoveries and world-class innovation, as well as preferential access to high potential deal flow and deep diligence expertise.

Proven strategy and profitable returns

We use our local world class research corridor as a lens to identify the most promising investment opportunities and apply our company creation strategy – a formula that has repeatedly proven its effectiveness with profitable returns.

Essential expertise for scale

We provide the critical expertise portfolio companies need to scale from great science on the bench to viable commercial enterprises competing in the global market. From thought leaders to executives to key advisors, our network and inhouse expertise give our companies the tools they need to perform.

Our Team

Expertise. Experience. Insight.

Deep subject knowledge, Robust industry relationships, Proven insight — meet the Genesys team.

The Genesys Team

Our team provides the deep domain expertise and experience needed to scale emerging opportunities in the lab into successful companies that will change the lives of countless patients around the world.

  • Jennifer Williams

    Jennifer Williams

    Chief Financial Officer

  • Damian Lamb

    Damian Lamb

    Co-founder, Managing Director

  • Lisa Low

    Lisa Low

    Senior Vice President, Finance

  • Kelly Holman

    Kelly Holman

    Co-founder, Managing Director

  • Sarah Farr

    Sarah Farr

    Senior Associate

  • Jamie Stiff

    Jamie Stiff

    Managing Director

  • Paras Sharma

    Paras Sharma

    Senior Associate

  • Genesys Capital

Our Portfolio

$250M invested
38 Companies
18 Exits

Our track record is a direct result of our approach to investment and company building.

World-first in vivo study: Cryostasis platform used in successful transplantation of mammalian organs preserved at sub-zero temperature.

PHILADELPHIA — Researchers from Toronto's University Health Network (UHN) have presented results using the Cryostasis platform to successfully transplant porcine kidneys preserved at below zero degrees C for 24 hrs, achieving full recovery with normal kidney function in all transplantations. The breakthrough results were presented at the American Society of Nephrology Annual Meeting in Philadelphia.

Fusion Pharmaceuticals To Present Interim Data From Phase 1 Trial Of FPI-1434 In Patients With Solid Tumors Expressing IGF-1R

HAMILTON, ON and BOSTON, June 26, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of interim data from the dose escalation portion of the Phase 1 trial...

Inversago Pharma Presents Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions

Montreal, Canada and San Diego, CA – June 23, 2023 – Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers...

Veralox Names Jonathan Mow as Chief Executive Officer as the Company Advances Development of First-in-Class Therapies for Immune-Mediated Diseases in Conjunction with Financing

FREDERICK, Md., June 20, 2023 (GLOBE NEWSWIRE) — Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies...

Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases

TORONTO, June 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that, with sponsorship and support from multiple physician specialty societies...

El Camino Health is first in the world to adopt FloPatch advanced ultrasound technology for sepsis management

MOUNTAIN VIEW, Calif., March 14, 2023 /PRNewswire/ — El Camino Health is the first health system in the world to adopt FloPatch, an innovative new technology that monitors blood flow in real time. Developed by Flosonics Medical, FloPatch is the world's first wireless, wearable Doppler ultra-sound system that helps clinicians better manage intravenous (IV) fluid therapy earlier in the sepsis care pathway.

Giiant Pharma Receives Financial Support From the US Crohn's and Colitis Foundation

MONTREAL–(BUSINESS WIRE) – FEBRUARY 24, 2023 - Giiant Pharma Inc., a Canadian, preclinical-stage biotech company, today announced that the Company will receive financial support from the US Crohn's and Colitis Foundation, through its IBD Ventures program, for an amount up to US$ 500,000.

Fusion Pharmaceuticals To Acquire Phase 2 Program For 225Ac-PSMA I&T, A Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer

HAMILTON, ON and BOSTON, Feb. 13, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) ("Fusion"), a clinical-stage oncology company focused on developing next-generation targeted alpha therapies ("TATs") as precision medicines...

For older news items, visit the Genesys News Archive here

Contact us

We’re listening!

Genesys Capital is located at Front St and University Ave in downtown Toronto, in the heart of the life science hub.